3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
5
Gastrointestinal
3
Other hematologic neoplasm
1
Head & Neck
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
20
Head and Neck Neoplasms
12
Nasopharyngeal Carcinoma
10
Sarcoma
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Nasopharyngeal Neoplasms
2
Mesothelioma
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Testicular Germ Cell Tumor
1
Recurrence
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Interventions
Cetuximab
14
Cisplatin
12
pembrolizumab
11
Paclitaxel
9
Gemcitabine
9
durvalumab
6
Nivolumab
6
Docetaxel
6
toripalimab
5
Carboplatin
5
Radiotherapy
4
Fluorouracil
4
Cyclophosphamide
4
fludarabine
3
Valproic Acid
3
Capecitabine
3
tremelimumab
2
spartalizumab
2
nimotuzumab
2
irinotecan sucrosofate
2
fludarabine phosphate
2
cemiplimab
2
anlotinib
2
Sunitinib
2
S 1 (combination)
2
Radiation
2
Oxaliplatin
2
NVP-BKM120
2
Methotrexate
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tislelizumab
×
Head & Neck
×
Clear all
NCT03924986
2025-01-31
RATIONALE-309
BeiGene
Phase 3
Completed
263 enrolled
19 charts